(Q37387943)

20 August 2017

1 reference

title

The history of multiple sclerosis: the changing frame of the disease over the centuries (English)

1 reference

20 August 2017

0 references

T Jock Murray

1

1 reference

20 August 2017

1 February 2009

1 reference

Journal of the Neurological Sciences

20 August 2017

1 reference

20 August 2017

277 Suppl 1

1 reference

20 August 2017

S3-8

1 reference

A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970003-6

Nuclear magnetic resonance imaging of the brain in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970003-6

Defining the clinical course of multiple sclerosis: Results of an international survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970003-6

Is multiple sclerosis caused by an oral spirochaete?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970003-6

Multiple Sclerosis is a chronic central nervous system infection by a spirochetal agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970003-6

Epstein-Barr virus in the development of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970003-6

Epstein-barr virus: environmental trigger of multiple sclerosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970003-6

Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970003-6

Multiple sclerosis. Trials of maintenance treatment with prednisolone and soluble aspirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970003-6

A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970003-6

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970003-6

The design of clinical studies to assess therapeutic efficacy in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970003-6

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970003-6

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970003-6

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970003-6

10.1016/S0022-510X(09)70003-6

7 January 2021

Identifiers

DOI

1 reference

release_7s6cpurg4zeqbm3qfyjcbglzju

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7s6cpurg4zeqbm3qfyjcbglzju

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

19200863

1 reference

PubMed ID

19200863